Citi analyst Patrick Donnelly raised the firm’s price target on Charles River (CRL) to $265 from $200 and keeps a Buy rating on the shares. The firm adjusted targets in the life science tools and diagnostics group after meeting with companies. Commentary around pharma was positive, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River price target raised to $231 from $224 at Baird
- Charles River Labs outlines 2026 outlook and acquisitions
- Charles River price target raised to $260 from $250 at Evercore ISI
- Charles River to buy KF Cambodia for $510M, exercises option for Pathoquest
- Charles River Labs Announces CEO Succession and Leadership Changes